• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Shire Completes Acquisition of Dyax

Article

January 22, 2016.

Shire (Dublin, Ireland) today announced that it has completed its acquisition of Dyax Corp. (Burlington, MA) in an all-cash transaction valued at approximately $5.9 billion, comprised of $37.30 in cash per Dyax share.

Dyax shareholders may receive additional value through a non-tradable contingent value right (CVR) that will pay $4.00 in cash per Dyax share upon approval of DX-2930 for hereditary angioedema (HAE), representing a potential additional $646 million in aggregate contingent consideration.

Shire’s Chief Executive Officer, Flemming Ornskov commented: “The addition of Kalbitor and DX-2930 to our portfolio strengthens our leadership position in HAE and, along with the commercial and research and development expertise at Dyax, is a clear strategic fit for us that advances our position as the global leader in rare diseases."

Recent Videos